With interim phase 2 data, Takeda’s dengue vaccine casts shadow on Sanofi
admin 7th November 2017 Uncategorised 0Takeda’s experimental dengue vaccine just became a clearer threat to Sanofi’s Dengvaxia as the latest 18-month interim phase 2 data showed Takeda’s shot induced sustained antibody responses, regardless of previous dengue exposure.
More: With interim phase 2 data, Takeda’s dengue vaccine casts shadow on Sanofi
Source: fierce